Canada's Drug Agency has made a pivotal decision regarding the coverage of a groundbreaking Alzheimer's therapy, potentially transforming access to treatment for Canadians. The therapy, priced at around $50,000 for 18 months of infusions, has been recommended for public reimbursement, marking a significant shift in the country's healthcare landscape.
This recommendation comes after a tumultuous journey. Initially, the agency issued a 'do-not-reimburse' stance in February 2026, citing concerns over the therapy's modest benefits for patients with mild cognitive impairment or mild dementia. However, a recent revision has turned the tide, with the agency now backing public coverage.
The therapy, known as lecanemab and sold as Leqembi, has already been approved in over 50 countries, including the United States, Japan, and the UK. Yet, public coverage remains a contentious issue, with varying policies across different regions. The US and Japan provide coverage under public health insurance, while the UK, despite licensing the drug, initially rejected it for routine NHS use due to cost-effectiveness concerns.
The Canadian scenario is particularly intriguing. The decision to cover the therapy publicly hinges on negotiations among provinces and territories, with the pan-Canadian Pharmaceutical Alliance playing a pivotal role. The therapy targets amyloid proteins in the brain, offering a glimmer of hope for slowing Alzheimer's progression in its early stages.
Michael Borrie, a renowned geriatrician, highlights the therapy's potential to slow cognitive decline and maintain patients' independence. The Alzheimer Society of Canada welcomes the recommendation, emphasizing its potential to make the therapy accessible to eligible Canadians. However, the final decision rests on expert committee advice and program sustainability considerations.
This development raises important questions about the future of Alzheimer's treatment in Canada. Will the therapy's approval lead to widespread adoption, and what implications will it have for the country's healthcare system? The journey of lecanemab through regulatory approval and public coverage highlights the complex interplay between innovation, cost, and patient care.
